Parkinson's disease (PD) is an insidious disease that affects the quality of life of over one and a half million people in the United States alone. In the past several decades, it has become accepted that PD occurs as a result of degeneration in dopaminergic cells in the substantia nigra pars compacta. Animal models have shown that this degeneration causes a cascade of changes in the functioning of inhibitory and excitatory neurotransmitters within the basal ganglia. However, three major shortcomings in our current understanding of PD still remain. First, there remains limited knowledge of how PD affects the functioning of specific nuclei of the basal ganglia in humans and how this relates to motor deficits that are impaired in PD. Second, although degeneration in the substantia nigra can be used to confirm PD at autopsy, there is limited knowledge in living humans linking structural degeneration in the substantia nigra with neuronal activation in the basal ganglia and cortex. Third, there is limited knowledge of how the basal ganglia and cortex are impaired in PD prior to patients taking dopaminergic medication (de novo PD). Over the past few years, our laboratory has developed new paradigms and methodology using functional magnetic resonance imaging (fMRI) to examine specific nuclei in the basal ganglia when healthy adults produce and select grip force output. The general view that has emerged is that posterior nuclei of the basal ganglia regulate basic parameters of continuous grip force output, whereas anterior nuclei of the basal ganglia regulate the internal selection of grip force amplitude. As such, the central hypothesis of this application is that due to degeneration in the substantia nigra, PD patients lose the ability to activate the anterior and posterior basal ganglia and cortex appropriately for different motor tasks. In order to test this hypothesis, we will study de novo patients with PD and healthy control subjects in two specific aims using both fMRI and diffusion tensor imaging (DTI).
Aims 1 a and 2a will use fMRI to study the functional abnormalities of the basal ganglia-thalamo-cortical loop during grip force tasks in de novo PD and control subjects.
Aims 1 b and 2b will combine DTI and fMRI in de novo PD to examine the relation between structural degeneration (DTI) in the substantia nigra and neuronal activation (fMRI) in the basal ganglia and cortex when PD patients perform different grip force tasks. The results of the proposed studies will provide the first evidence in humans linking task-specific motor deficits in PD with structural degeneration in the substantia nigra and neuronal activation in the basal ganglia and cortex.

Public Health Relevance

Parkinson's disease affects over one and a half million people in the US alone, and patients with Parkinson's disease have significant problems controlling movement. These problems are thought to be related to structural degeneration in a region of the brain called the substantia nigra, which in turn is part of a brain region known to be important for movement control called the basal ganglia. This will be the first study in humans to determine how specific motor tasks alter the link between structural degeneration in the substantia nigra and neuronal activation in specific nuclei of the basal ganglia. The study will use functional and high-resolution structural brain imaging to examine the basal ganglia and other brain regions in patients with Parkinson's disease as they perform different motor tasks and compare them to people without the disease. Since very little is known regarding the brain function of Parkinson's disease prior to taking medication, we will perform our studies before patients begin a drug treatment program for the disease.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Research Project (R01)
Project #
Application #
Study Section
Motor Function, Speech and Rehabilitation Study Section (MFSR)
Program Officer
Chen, Daofen
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Illinois at Chicago
Schools of Allied Health Profes
United States
Zip Code
Burciu, Roxana G; Vaillancourt, David E (2018) Imaging of Motor Cortex Physiology in Parkinson's Disease. Mov Disord 33:1688-1699
Chung, Jae Woo; Burciu, Roxana G; Ofori, Edward et al. (2018) Beta-band oscillations in the supplementary motor cortex are modulated by levodopa and associated with functional activity in the basal ganglia. Neuroimage Clin 19:559-571
Hupfeld, Kathleen E; Vaillancourt, David E; Seidler, Rachael D (2018) Genetic markers of dopaminergic transmission predict performance for older males but not females. Neurobiol Aging 66:180.e11-180.e21
Burciu, Roxana G; Seidler, Rachael D; Shukla, Priyank et al. (2018) Multimodal neuroimaging and behavioral assessment of ?-synuclein polymorphism rs356219 in older adults. Neurobiol Aging 66:32-39
Helmich, Rick C; Vaillancourt, David E; Brooks, David J (2018) The Future of Brain Imaging in Parkinson's Disease. J Parkinsons Dis 8:S47-S51
Chung, Jae W; Ofori, Edward; Misra, Gaurav et al. (2017) Beta-band activity and connectivity in sensorimotor and parietal cortex are important for accurate motor performance. Neuroimage 144:164-173
Lehericy, St├ęphane; Vaillancourt, David E; Seppi, Klaus et al. (2017) The role of high-field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward. Mov Disord 32:510-525
Chung, Jae Woo; Burciu, Roxana G; Ofori, Edward et al. (2017) Parkinson's disease diffusion MRI is not affected by acute antiparkinsonian medication. Neuroimage Clin 14:417-421
Vaillancourt, David E (2017) What Would Dr. James Parkinson Think Today? Tau and Other Imaging Possibilities in Parkinson's Disease. Mov Disord 32:805-806
Burciu, Roxana G; Ofori, Edward; Archer, Derek B et al. (2017) Progression marker of Parkinson's disease: a 4-year multi-site imaging study. Brain 140:2183-2192

Showing the most recent 10 out of 71 publications